Menu Search
Equities

Glenmark Pharmaceuticals Ltd

GLENMARK:NSI

Glenmark Pharmaceuticals Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,478.20
  • Today's Change10.20 / 0.69%
  • Shares traded517.71k
  • 1 Year change+90.02%
  • Beta1.1612
Data delayed at least 15 minutes, as of Nov 22 2024 10:16 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy4
Outperform1
Hold4
Sell1
Strong Sell0

Share price forecast in INR

The 12 analysts offering 12 month price targets for Glenmark Pharmaceuticals Ltd have a median target of 1,650.00, with a high estimate of 2,036.00 and a low estimate of 570.00. The median estimate represents a 11.64% increase from the last price of 1,478.00.
High37.8%2,036.00
Med11.6%1,650.00
Low-61.4%570.00

Dividends in INR

In 2024, Glenmark Pharmaceuticals Ltd reported a dividend of 2.50 INR, equaling last years dividend. The 6 analysts covering the company expect dividends of 3.56 INR for the upcoming fiscal year, an increase of 42.48%.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates in INR

On May 24, 2024, losses of -27.65 per share.
The next earnings announcement is expected on May 26, 2025.
Average growth rate-9.39%
Glenmark Pharmaceuticals Ltd reported annual 2024 losses of -35.37 per share on May 24, 2024.
Average growth rate+14.31%
More ▼

Revenue history & estimates in INR

Glenmark Pharmaceuticals Limited had 2nd quarter 2025 revenues of 34.34bn. This bettered the 34.21bn consensus of the 6 analysts covering the company. This was 2.93% above the prior year's 2nd quarter results.
Average growth rate+3.03%
Glenmark Pharmaceuticals Limited had revenues for the full year 2024 of 118.13bn. This was 7.52% below the prior year's results.
Average growth rate+2.90%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.